Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Arrhythmogenic right ventricular cardiomyopathy 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
2 Arrhythmogenic right ventricular cardiomyopathy 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
3 Arrhythmogenic right ventricular cardiomyopathy 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
4 Arrhythmogenic right ventricular cardiomyopathy 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
5 Cell adhesion molecules 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
6 Cell adhesion molecules 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
7 Cell adhesion molecules 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
8 Cell adhesion molecules 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
9 Dilated cardiomyopathy 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
10 Dilated cardiomyopathy 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
11 Dilated cardiomyopathy 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
12 Dilated cardiomyopathy 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
13 ECM-receptor interaction 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
14 ECM-receptor interaction 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
15 ECM-receptor interaction 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
16 ECM-receptor interaction 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
17 Focal adhesion 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
18 Focal adhesion 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
19 Focal adhesion 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
20 Focal adhesion 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
21 Hematopoietic cell lineage 💬
1件: ITGA4 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
22 Hematopoietic cell lineage 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
23 Hematopoietic cell lineage 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
24 Hematopoietic cell lineage 💬
1件: ITGA4 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
25 Human papillomavirus infection 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
26 Human papillomavirus infection 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
27 Human papillomavirus infection 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
28 Human papillomavirus infection 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
29 Hypertrophic cardiomyopathy 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
30 Hypertrophic cardiomyopathy 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
31 Hypertrophic cardiomyopathy 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
32 Hypertrophic cardiomyopathy 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
33 Intestinal immune network for IgA production 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
34 Intestinal immune network for IgA production 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
35 Intestinal immune network for IgA production 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
36 Intestinal immune network for IgA production 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
37 Leishmaniasis 💬
1件: ITGA4 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
38 Leishmaniasis 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
39 Leishmaniasis 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
40 Leishmaniasis 💬
1件: ITGA4 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
41 Leukocyte transendothelial migration 💬
1件: ITGA4 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
42 Leukocyte transendothelial migration 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
43 Leukocyte transendothelial migration 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
44 Leukocyte transendothelial migration 💬
1件: ITGA4 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
45 PI3K-Akt signaling pathway 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
46 PI3K-Akt signaling pathway 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
47 PI3K-Akt signaling pathway 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
48 PI3K-Akt signaling pathway 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
49 Regulation of actin cytoskeleton 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
50 Regulation of actin cytoskeleton 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
51 Regulation of actin cytoskeleton 💬
2件: ITGA4, ITGB7 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
52 Regulation of actin cytoskeleton 💬
2件: ITGA4, ITGB7 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬
53 Yersinia infection 💬
1件: ITGA4 💬 Abrilumab 💬 Abrilumab 2件: 96, 97 💬
54 Yersinia infection 💬
1件: ITGA4 💬 Firategrast 💬 Firategrast 1件: 13 💬
55 Yersinia infection 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
56 Yersinia infection 💬
1件: ITGA4 💬 Vedolizumab 💬 Vedolizumab 3件: 94, 96, 97 💬